Researchers sought to determine whether genomic evaluation in patients with BCR-ABL1 negative B-ALL may improve risk assessments.
About half of patients with impaired seroconversion after the first dose of a COVID-19 vaccine still had low antibody levels after the second dose.
Researchers sought to determine whether higher-intensity thromboprophylaxis may be necessary for reducing the risk of VTE in younger patients with multiple myeloma.
Relapse-free survival outcomes were similar between real-world and clinical trial patients.
The intervention also improved the rate of advance directive completion.
Cardiovascular disease-related warnings also took longer to be issued.
Patients treated at facilities with a high use of neoadjuvant chemotherapy had greater declines in 1-year mortality rates over time.
PD-L1 expression and tumor mutational burden were not associated with survival.
Enrollment declined 43% from 2019 to 2020.
Factors associated with poor survival were advanced age and male sex.
